СПИД-ассоциированные лимфомы у детей

СПИД-ассоциированные лимфомы у детей

Автор: Павлова Т.Ю., Валиев Т.Т.

Журнал: Вестник гематологии @bulletin-of-hematology

Рубрика: Обзор литературы

Статья в выпуске: 2 т.19, 2023 года.

Бесплатный доступ

Лимфомы являются наиболее распространенными злокачественными новообразованиями у пациентов с ВИЧ-инфекцией. За последние десятилетия использование стандартных режимов противоопухолевого лечения наряду с комбинированной антиретровирусной терапией показало значительное улучшение показателей выживаемости пациентов с ВИЧ-ассоциированными лимфомами. В настоящем обзоре мы обсуждаем частоту ВИЧ/ СПИД-ассоциированных лимфом, их клинические особенности и последние достижения в терапии. Представляем собственный опыт диагностики и лечения 5 случаев злокачественных лимфом у детей с ВИЧ-инфекцией за 30-летний период (с 1989 по 2019 гг.). Преобладание агрессивных вариантов лимфом в педиатрической когорте ВИЧ-инфицированных пациентов, более глубокая иммуносупрессия, обусловленная инициальной незрелостью иммунной системы и необходимость проведения одновременной антиретровирусной и противоопухолевой терапии – основные постулаты в работе онкогематолога, проводящего лечение ВИЧ/СПИД-ассоциированных лимфом у детей. Эффективная антиретровирусная терапия в сочетании с полным арсеналом сопроводительной терапии позволяет проводить в полном объеме современное противоопухолевое лечение, включая таргетные препараты и трансплантационные технологии. Подобный подход способствует достижению высоких показателей выживаемости детей с ВИЧ-ассоциированными лимфомами практически аналогичных таковым в группе больных без ВИЧ-инфекции.

Еще

Вирус иммунодефицита человека, синдром приобретенного иммунодефицита, лимфомы, неходжкинские лимфомы, лимфома Ходжкина, антиретровирусная терапия, мутации лекарственной резистентности, дети

Короткий адрес: https://sciup.org/170199859

IDR: 170199859

Список литературы СПИД-ассоциированные лимфомы у детей

  • “UNAIDS 2019 estimates, Global AIDS Monitoring,” 2019, http://aidsinfo.unaids.org.
  • Prendergast A.J., Klenerman P., Goulder P.J. The impact of differential antiviral immunity in children and adults. // Nat Rev Immunol. – 2012. – Vol. 12, N 9. – P. 636-48.
  • Gianesin K., Freguja R., Carmona F. et al. The role of genetic variants of Stromal Cell-Derived Factor 1 in pediatric HIV-1 infection and disease progression. // PLoS One. – 2012. – Vol. 7, N 9. – P. e44460.
  • De Rossi A., Masiero S., Giaquinto C. et al. Dynamics of viral replication in infants with vertically acquired human immunodeficiency virus type 1 infection. // J Clin Invest. – 1996. – Vol. 97, N 2. – P. 323-330.
  • Henrard D.R., Phillips J.F., Muenz L.R. et al. Natural history of HIV-1 cell-free viremia. // JAMA. – 1995. – Vol. 274, N 7. – P. 554-558.
  • Côté H.C., Soudeyns H., Thorne A. et al. Leukocyte telomere length in HIV-infected and HIV-exposed uninfected children: shorter telomeres with uncontrolled HIV viremia. // PLoS One. – 2012. – Vol. 7, N 7. – P. e39266.
  • Méndez-Lagares G., Díaz L., Correa-Rocha R. et al. Specific patterns of CD4-associated immunosenescence in vertically HIV-infected subjects. // Clin Microbiol Infect. – 2013. – Vol. 19, N 6. – P. 558-565.
  • Hazra R., Siberry G.K., Mofenson L.M. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. // Annu Rev Med. – 2010. – Vol. 61. – P. 169-185.
  • Guaraldi G., Palella FJ. Clinical implications of aging with HIV infection: perspectives and the future medical care agenda. // AIDS. – 2017. – Vol. 31, Suppl 2. – P. S129-S135.
  • Chiappini E., Bianconi M., Dalzini A. et al. Accelerated aging in perinatally HIV-infected children: clinical manifestations and pathogenetic mechanisms. // Aging (Albany NY). – 2018. – Vol. 10, N 11. – P. 3610-3625.
  • Пивник А.В., Туманова М.В., Серегин Н.В. и другие. Лимфомы у ВИЧ-инфицированных больных: обзор литературы. //Клин. Онкогематол. – 2014. Т. 7б № 3. – С. 264–277.
  • Deeks S.G., Lewin S.R., Havlir D.V. The end of AIDS: HIV infection as a chronic disease. Lancet. // 2013. – Vol. 382, N 9903. – P. 1525-1533.
  • Nakagawa F., May M., Phillips A. Life expectancy living with HIV: recent estimates and future implications. // Curr Opin Infect Dis. – 2013. – Vol. 26, N 1. – P. 17-25.
  • May M.T., Gompels M., Delpech V. et al. UK Collaborative HIV Cohort (UK CHIC) Study. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. // AIDS. – 2014. – Vol. 28, N 8. – P. 1193-11202.
  • Wing E.J. HIV and aging. // Int J Infect Dis. – 2016. – Vol. 53. – P. 61-68.
  • IeDEA Pediatric Working Group. Taking a critical look at the UNAIDS global estimates on paediatric and adolescent HIV survival and death. // J Int AIDS Soc. – 2017. – Vol. 20, N 1. – P. 21952.
  • Rickabaugh T.M., Kilpatrick R.D., Hultin L.E. et al. The dual impact of HIV-1 infection and aging on naïve CD4 T-cells: additive and distinct patterns of impairment. // PLoS One. – 2011. – Vol. 6, N 1. – P. e16459.
  • Effros R.B., Fletcher C.V., Gebo K. et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. // Clin Infect Dis. – 2008. – Vol. 47, N 4. – P. 542-553.
  • Kennedy B.K., Berger S.L., Brunet A. et al. Geoscience: linking aging to chronic disease. // Cell. – 2014. – Vol. 159, N 4. – P. 709-713.
  • Lagathu C., Cossarizza A., Béréziat V. et al. Basic science and pathogenesis of ageing with HIV: potential mechanisms and biomarkers. // AIDS. – 2017. – Vol. 31, Suppl 2. – P. S105-S119.
  • Hewitt G., Jurk D., Marques F.D. et al. Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence. // Nat Commun. – 2012. – Vol. 3. – P. 708.
  • Armanios M., Blackburn E.H. The telomere syndromes. // Nat Rev Genet. – 2012. – Vol. 13, N 10. – P. 693-704.
  • Armanios M., Alder J.K., Parry E.M. et al. Short telomeres are sufficient to cause the degenerative defects associated with aging. // Am J Hum Genet. – 2009. – Vol. 85, N 6. – P. 823-832.
  • Ballon G., Ometto L., Righetti E. et al. Human immunodeficiency virus type 1 modulates telomerase activity in peripheral blood lymphocytes. // J Infect Dis. – 2001. – Vol. 183, N 3. – P. 417-424.
  • Franzese O., Adamo R., Pollicita M. et al. Telomerase activity, hTERT expression, and phosphorylation are downregulated in CD4(+) T lymphocytes infected with human immunodeficiency virus type 1 (HIV-1). // J Med Virol. – 2007. – Vol. 79, N 5. – P. 639-646.
  • Weng N.P., Levine B.L., June C.H. et al. Regulated expression of telomerase activity in human T lymphocyte development and activation. // J Exp Med. – 1996. – Vol. 183, N 6. – P. 2471-2479.
  • Biggar R.J., Chaturvedi A.K., Goedert J.J. et al. HIV/AIDS Cancer Match Study. AIDS-related cancer and severity of immunosuppression in persons with AIDS. // J Natl Cancer Inst. – 2007. – Vol. 99, N. 12. – P. 962-972.
  • Chiappini E., Galli L., Tovo P.A. et al; Italian Register for HIV Infection in Children. Cancer rates after year 2000 significantly decrease in children with perinatal HIV infection: a study by the Italian Register for HIV Infection in Children. // J Clin Oncol. – 2007. – Vol. 25, N 1. – P. 97-101.
  • Biggar R.J., Frisch M., Goedert J.J. Risk of cancer in children with AIDS. AIDS-Cancer Match Registry Study Group. // JAMA. – 2000. – Vol. 284, N 2. – P. 205-209.
  • Petrara M.R., Freguja R., Gianesin K. et al. Epstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infection. // Front Microbiol. – 2013. – Vol. 4. – P. 311.
  • Breen E.C., Hussain S.K., Magpantay L. et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. // Cancer Epidemiol Biomarkers Prev. – 2011. – Vol. 20, N 7. – P. 1303-1314.
  • Petrara M.R., Penazzato M., Massavon W. et al. Epstein-Barr virus load in children infected with human immunodeficiency virus type 1 in Uganda. // J Infect Dis. – 2014. – Vol. 210, N 3. – P. 392-329.
  • Regidor D.L., Detels R., Breen E.C. et al. Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. // AIDS. – 2011. – Vol. 25, N 3. – P. 303-314. doi:
  • Douek D.C., Roederer M., Koup R.A. Emerging concepts in the immunopathogenesis of AIDS. // Annul Rev Med. – 2009. – Vol. 60. – P. 471-484.
  • Campisi J., Andersen J.K., Kapahi P. et al. Cellular senescence: a link between cancer and age-related degenerative disease? // Semin Cancer Biol. – 2011. – Vol. 21, N 6. – P. 354-359.
  • Castelli R., Schiavon R., Preti C. et al. HIV-Related Lymphoproliferative Diseases in the Era of Combination Antiretroviral Therapy. // Cardiovasc Hematol Disord Drug Targets. – 2020. – Vol. 20, N 3. – P. 175-180.
  • Lewden C., May T., Rosenthal E. et al. ANRS EN19 Mortalité Study Group and Mortavic1. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). // J Acquir Immune Defic Syndr. – 2008. – Vol. 48, N 5. – P. 590-598.
  • Grulich A.E., Li Y., McDonald A.M. et al. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. // AIDS. – 2001. – Vol. 15, N 5. – P. 629-33.
  • Swerdlow S.H., Campo E., Pileri S.A. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. // Blood. – 2016. – Vol. 127, N 20. – P. 2375-2390.
  • Schommers P., Hentrich M., Hoffmann C. et al. Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort. // Br J Haematol. – 2015. – Vol. 168, N 6. – P. 806-810.
  • Wyen C., Jensen B., Hentrich M. et al. Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients. // AIDS. – 2012. – Vol. 26, N 4. – P. 457-464.
  • Gibson T.M., Morton L.M., Shiels M.S. et al. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. // AIDS. – 2014. - Vol. 28, N 15. – P. 2313-2318.
  • Dozzo M., Carobolante F., Donisi P.M. et al. Burkitt lymphoma in adolescents and young adults: management challenges. // Adolesc Health Med Ther. – 2016. – Vol. 23, N 8. – P. 11-29.
  • Kaplan L.D., Ai W. AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma. // UpToDate, 2017.
  • Barnes J.A., Lacasce A.S., Feng Y. et al. Evaluation of the Addition of Rituximab to CODOX-M/IVAC for Burkitt’s Lymphoma: A Retrospective Analysis. // Ann Oncol. – 2011. – Vol. 22, N 8. – P. 1859–1864.
  • Makis W., Ciarallo A., Lisbona R. Plasmablastic lymphoma of the oral cavity in an HIV-positive patient: staging with 18F-FDG PET/CT. // Acta Radiol. – 2011. – Vol. 52, N 9. – P. 970-972.
  • Borie R., Cadranel J., Guihot A. et al. Pulmonary manifestations of human herpesvirus-8 during HIV infection. // Eur Respir J. – 2013. – Vol. 42, N 4. – P. 1105-1118.
  • Gabarre J., Raphael M., Lepage E. et al; Groupe d'Etude des Lymphomes de l'Adulte (GELA). Human immunodeficiency virus-related lymphoma: relation between clinical features and histologic subtypes. // Am J Med. – 2001. – Vol. 111, N 9. – P. 704-711.
  • Jacobson C.A., Abramson J.S. HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART. // Adv Hematol. – 2012. – Vol. 2012. – P. 507257.
  • Brackers de Hugo L., Ffrench M., Broussolle C. et al. Granulomatous lesions in bone marrow: clinicopathologic findings and significance in a study of 48 cases. // Eur J Intern Med. – 2013. – Vol. 24, N 5. – P. 468-473.
  • Lawn S.D., Török M.E., Wood R. Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. // Curr Opin Infect Dis. – 2011. – Vol. 24, N 1. – P. 34-42.
  • Powles T., Imami N., Nelson M. et al. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. // AIDS. – 2002. – Vol. 16, N 4. – P. 531-536.
  • Bandera A., Gori A., Clerici M. et al. Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance. // Curr Opin Pharmacol. – 2019. – Vol. 48. – P. 24-32.
  • Lorenzo-Redondo R., Fryer H.R., Bedford T. et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. // Nature. – 2016. – Vol. 530. – P. 51-56.
  • Wang Z., Gurule E.E., Brennan T.P. et al Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane. // Proc Natl Acad Sci U S A. – 2018. – Vol. 115, N 11. – P. E2575-E2584.
  • Lohse N., Obel N. Update of Survival for Persons with HIV Infection in Denmark. // Ann Intern Med. – 2016. – Vol. 165, N 10. – P. 749-750.
  • Patel P., Hanson D.L., Sullivan P.S. et al. Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. // Ann Intern Med. – 2008. – Vol. 148, N 10. – P. 728-736.
  • Seaberg E.C., Wiley D., Martínez-Maza O. et al; Multicenter AIDS Cohort Study (MACS). Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. // Cancer. – 2010. – Vol. 116, N 23. – P. 5507-5516.
  • Silverberg M.J., Lau B., Achenbach C.J. et al. North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS. Cumulative Incidence of Cancer Among Persons with HIV in North America: A Cohort Study. // Ann Intern Med. – 2015. – Vol. 163, N 7. – P. 507-518.
  • Martorelli D., Muraro E., Mastorci K. et al. A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: implications for EBV-driven lymphomagenesis in the HIV setting. // Int J Cancer. – 2015. – Vol. 137, N 6. – P. 1374-1385.
  • Landgren O, Goedert JJ, Rabkin C.S. et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. // J Clin Oncol. – 2010. – Vol. 28, N 5. – P. 773-779.
  • Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Bohlius J., Schmidlin K., Costagliola D. et al. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combinationantiretroviral therapy: a European multicohort study. // Antivir Ther. – 2009. – Vol. 14, N 8. – P. 1065-1074.
  • Silverberg M.J., Neuhaus J., Bower M. et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. // AIDS. – 2007. – Vol. 21, N 14. – P. 1957-1963.
Еще
Статья научная
SciUp 2024 © 2024 ©